Triazolam

More frequently reported side effects include: dizziness, insomnia, rebound insomnia, headache, and irritability. See below for a comprehensive list of adverse effects.

Applies to triazolam: oral tablet

Along with its needed effects, triazolam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking triazolam:

Less common

• Shakiness and unsteady walk
• unsteadiness, trembling, or other problems with muscle control or coordination

Rare

• Being forgetful
• burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• continuing ringing or buzzing or other unexplained noise in the ears
• discouragement
• false or unusual sense of well-being
• fast, pounding, or irregular heartbeat or pulse
• feeling sad or empty
• hearing loss
• irritability
• lack of appetite
• loss of interest or pleasure
• nightmares
• tiredness
• trouble concentrating
• trouble sleeping

Incidence not known

• Abdominal or stomach pain
• actions that are out of control
• aggressiveness
• anxiety
• changes in patterns and rhythms of speech
• chest pain
• chills
• clay-colored stools
• confusion about identity, place, and time
• dark urine
• decrease in frequency of urination
• decrease in urine volume
• difficulty in passing urine (dribbling)
• dizziness
• drowsiness
• dry mouth
• environment seems unreal
• fainting
• falling
• false beliefs that cannot be changed by facts
• feeling of unreality
• fever
• headache
• hyperventilation
• inability to move the eyes
• increased blinking or spasms of the eyelid
• increased muscle spasm
• irregular heartbeats
• loss of bladder control
• loss of memory
• nausea
• nervousness
• nightmares
• painful urination
• problems with memory
• rash
• relaxed and calm
• restlessness
• seeing, hearing, or feeling things that are not there
• sense of detachment from self or body
• sleep walking
• sleepiness
• slurred speech
• sticking out of tongue
• talking, feeling, and acting with excitement
• trouble breathing, speaking, or swallowing
• uncontrolled twisting movements of the neck, trunk, arms, or legs
• unpleasant breath odor
• unusual excitement, nervousness, restlessness, or irritability
• unusual facial expressions
• unusual tiredness or weakness
• vomiting of blood
• yellow eyes or skin

Some side effects of triazolam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Lightheadedness

Rare

• Any change in vision
• blistering, crusting, irritation, itching, or reddening of the skin
• change in taste, or bad, unusual, or unpleasant (after) taste
• cracked, dry, or scaly skin
• cramps
• diarrhea
• difficulty having a bowel movement (stool)
• dry mouth
• swelling
• weakness

Incidence not known

• Decreased interest in sexual intercourse
• inability to have or keep an erection
• increase in sexual ability, desire, drive, or performance
• increase interest in sexual intercourse
• itching skin
• loss in sexual ability, desire, drive, or performance
• menstrual changes
• redness, swelling, or soreness of the tongue
• swelling or inflammation of the mouth
• weight loss

Applies to triazolam: oral tablet

The most commonly reported side effects included drowsiness/sedation, dizziness/lightheadedness, headache, and ataxia.

Very common (10% or more): Sedation (up to 19.4%), drowsiness (up to 14%)

Common (1% to 10%): Anterograde amnesia with appropriate/inappropriate behavior, ataxia, concentration difficulty, coordination disorders/impaired coordination, dizziness, headache, impaired equilibrium, lethargy, lightheadedness, memory impairment

Rare (0.01% to 0.1%): Dysesthesia, paresthesia, taste alterations

Frequency not reported: Amnestic symptoms, clouding of consciousness, dysarthria, dystonia, slurred speech, somnambulism, syncope

Complex behaviors, such as "sleep-driving", other behaviors such as preparing and eating food, making phone calls, or having sex, with amnesia for these events, have been reported at therapeutic doses with this medicine.

Very common (10% or more): WBC/high power field (HPF) in urinalysis (up to 11.3%)

Common (1% to 10%): Albuminuria, red blood cells/HPF in urinalysis

Frequency not reported: Incontinence, menstrual irregularities, urinary retention

Very common (10% or more): Low eosinophil count (up to 10.2%)

Common (1% to 10%): High eosinophil count, low monocyte count, low/high basophil count, low/high lymphocyte count, low/high neutrophil count, low/high WBC count

Common (1% to 10%): High bilirubin, increased alkaline phosphatase, low/high creatinine

Frequency not reported: Anorexia

Rebound insomnia (a worsening of sleep following cessation of therapy) has been observed and has sometimes been reported to occur in association with increased daytime anxiety.

Withdrawal symptoms have included agitation, restlessness, anxiety, insomnia, psychosis, delirium, convulsions, tremor, abdominal cramps, blurred vision, vomiting, and sweating.

Worsening of insomnia, depression, or the emergence of new thinking or behavior abnormalities, including suicidal thinking, have emerged during treatment with sedative-hypnotic drugs, including this drug. The frequency and extent to which this drug is associated with adverse behavioral effects is controversial.

One study based on the postmarketing surveillance Spontaneous Reporting System of the FDA has suggested that adverse behavioral reactions have been reported 22 to 99 times more frequently in association with triazolam therapy than with temazepam therapy for insomnia. An increased frequency of adverse behavioral effects was noted to occur most frequently in elderly patients and at higher doses of this drug. The methodology of this study, however, has been questioned on the grounds that spontaneous reports of adverse effects do not necessarily correlate with the incidence of adverse effects.

Other studies and reports have concluded that little evidence exists to support the contention that this drug is associated with a greater risk of adverse behavioral effects than other benzodiazepines (including temazepam).

Common (1% to 10%): Anxiety, nervousness

Uncommon (0.1% to 1%): Confusional states, depression, euphoria

Rare (0.01% to 0.1%): Dreaming, insomnia, nightmares

Frequency not reported: Abnormal dreams, abuse, acute rage, addiction, aggressiveness, agitation, agitational state, bizarre behavior, changes in libido, delusions, depersonalization, derealization, disorientation, disorientation in time/place, excitation, hallucinations, inappropriate behavior, irritability, mania, other adverse behavioral effects, paranoia, restlessness, sleep disturbances, stimulation

Common (1% to 10%): Nausea, vomiting

Rare (0.01% to 0.1%): Constipation, diarrhea, dry mouth

Frequency not reported: Burning tongue, glossitis, stomatitis

Common (1% to 10%): Tiredness

Uncommon (0.1% to 1%): Pain

Rare (0.01% to 0.1%): Tinnitus, weakness

Frequency not reported: Falling, paradoxical reactions

Death from hepatic failure has been reported in a patient also receiving diuretic drugs.

Common (1% to 10%): High AST levels

Rare (0.01% to 0.1%): Death (from hepatic failure)

Frequency not reported: Jaundice

Uncommon (0.1% to 1%): Pruritus, skin rash

Rare (0.01% to 0.1%): Dermatitis

Uncommon (0.1% to 1%): Palpitations, tachycardia

Frequency not reported: Chest pain

Uncommon (0.1% to 1%): Hiccups

Rare (0.01% to 0.1%): Congestion

One study of patients with obstructive sleep apnea has suggested that this drug may increase the maximum apnea duration and lower the minimum oxygen saturation of apneic patients.

Uncommon (0.1% to 1%): Cramps

Frequency not reported: Increased muscle spasticity

Uncommon (0.1% to 1%): Visual disturbances

Rare (0.01% to 0.1%): Allergy

Postmarketing reports: Anaphylactic shock, anaphylactoid reaction, allergic edema, angioneurotic edema, hypersensitivity reaction